Resolute Integrity Zotarolimus-eluting coronary stent system
The Resolute Integrity stent is a metal stent with the drug Zotarolimus contained in a thin coating on the stent’s surface. It uses the same stent design, base material, and manufacturing process as the approved uncoated Integrity Coronary Stent. The Resolute Integrity stent uses the same drug as the approved Endeavor Zotarolimus-Eluting Coronary Stent. However, the Resolute Integrity stent uses a different polymer in the drug-polymer stent coating and a different delivery system than the Endeavor system.
The Resolute Integrity stent is mounted on a folded balloon attached to a catheter delivery system for placement into a coronary artery.
A catheter with a small balloon mounted on the end is inserted into a blood vessel in the groin or arm and advanced into a coronary artery. The catheter is then positioned at the narrowed portion of the artery and the balloon is inflated. As the balloon inflates, it stretches the coronary artery wall ( a procedure known as balloon angioplasty ). The balloon is then deflated, and the catheter is removed from the artery.
The Resolute Integrity stent delivery catheter is then positioned at the narrowing of the coronary artery. The balloon on the stent delivery catheter is inflated, which expands the stent and presses it against the coronary artery wall. This may be followed by repeated balloon inflations within the stent to achieve the desired stent expansion. The stent remains permanently implanted within the coronary artery to help keep the artery open.
The drug ( Zotarolimus ) is released over time into the artery wall around the stent to help prevent the vessel from re-narrowing.
The Resolute Integrity stent is used in patients who have a narrowing in their coronary arteries caused by coronary artery disease, a condition that occurs when the arteries that supply oxygen-rich blood and nutrients to the heart muscle become narrowed or blocked by a gradual build-up of plaque.
Plaque is made up of fatty deposits ( cholesterol ), white blood cells, calcium, and scar tissue that collect over time in the coronary artery wall. If these arteries become blocked or narrowed, treatment may be required to improve blood flow and increase the supply of oxygen to the heart.
The Resolute Integrity stent is used in patients, including those with diabetes mellitus, who have narrowing in coronary arteries with a length less than or equal to 35 mm with reference vessel diameters of greater than or equal to 2.25 mm to less than or equal to 4.2 mm.
Placement of the Resolute Integrity stent within the narrowed coronary artery improves blood flow. After a coronary artery stent is implanted, re-narrowing of the artery may occur. Zotarolimus is released over time from the Resolute Integrity stent surface into the nearby artery wall to help prevent re-narrowing of the vessel.
The Resolute Integrity Zotarolimus-Eluting Coronary Stent System should not be used in patients who: a) cannot receive antiplatelet and/or blood-thinning ( anticoagulation ) therapy; have a lesion that prevents complete angioplasty balloon inflation or proper placement of the stent or stent delivery system; have known hypersensitivity or allergy to Acetylsalicylic acid ( Aspirin ), Heparin, Bivalirudin, Clopidogrel, Prasugrel, Ticlopidine, Zotarolimus, Tacrolimus, Sirolimus, Everolimus, or similar drugs or any other analogue or derivative; have a known hypersensitivity or contraindication to structurally-related compounds Cobalt, Nickel, Chromium, Molybdenum, acrylic, and fluoropolymers. ( Xagena )
Source: FDA, 2014
Percutaneous venous angioplasty in patients with multiple sclerosis and chronic cerebrospinal venous insufficiency
Venous percutaneous transluminal angioplasty ( vPTA ) in patients with multiple sclerosis ( MS ) and chronic cerebrospinal venous insufficiency...
MATRIX trial: Bivalirudin shows mixed results in patients with acute coronary syndrome. Radial access reduces net adverse events
Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and...
The FDA ( Food and Drug Administration ) has cleared for marketing the ENROUTE Transcarotid Neuroprotection System ( ENROUTE TNS...
Higher risk of silent infarction in the brain on MRI after carotid angioplasty and stenting in comparison with carotid endarterectomy
Silent infarction in the brain can be detected in around 34% of patients after carotid endarterectomy ( CEA ) and...
High-risk patients with intracranial artery stenosis: aggressive medical treatment with or without stenting
Early results of the SAMMPRIS ( Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis ) trial...
Carotid revascularization therapies: carotid angioplasty and stenting linked to higher risk of perioperative mortality, stroke, and unfavorable discharges than carotid endarterectomy
Clinical equipoise of carotid revascularization therapies remains controversial. Researchers sought to determine whether adverse outcomes after carotid endarterectomy ( CEA...
The European Medicines Agency ( EMA ), the Committee for Medicinal Products for Human Use ( CHMP ), and the...
Atherosclerotic renal artery stenosis: PTRA or PTRAS does not improve outcomes compared with medical therapy
The aim of a study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal...
Women suffer more disabling strokes than men and need to become better aware of their unique risk factors, according to...